VistaGen Therapeutics Faces Dual Securities Class Actions Over Fasedienol, PALISADE‑2 Disclosures

Two Firms File Class Actions Against VistaGen

VistaGen Therapeutics faces parallel securities class actions filed by The Schall Law Firm and DJS Law Group alleging the company made false and misleading statements about its drug candidate fasedienol and the PALISADE‑2 trial. Both complaints cover the same class period, April 1, 2024 through December 16, 2025, and cite alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b‑5.

Allegations Over PALISADE‑2 Disclosures

The complaints contend VistaGen misrepresented the PALISADE‑2 results and created a misleading impression that fasedienol is likely to succeed in Phase 3, while downplaying the risk of clinical failure. Plaintiffs say the company’s public statements during the class period are false and materially misleading and that investors suffered losses when the disclosures proved inaccurate. The suits seek to hold VistaGen accountable for alleged inflation of its market valuation through those statements.

Both law firms frame their filings around similar factual claims about management commentary and investor communications, and each seeks to recover damages for affected shareholders through class litigation. DJS Law Group additionally promotes potential lead plaintiff appointments but notes appointment is not required for participation. The Schall complaint emphasizes that class certification has not yet occurred and that investors are not represented by counsel until certification.

Industry Disclosure Implications

The litigation underscores heightened scrutiny on biotech companies’ public characterizations of clinical readouts and forward‑looking statements. Legal threats over trial messaging may prompt biopharma firms to tighten investor communications, provide more cautious risk disclosures, and detail trial limitations to avoid allegations of overstating likelihood of success.

Procedural Notices and Deadlines

Both firms urge shareholders who purchased VistaGen securities during the class period to act before a March 16, 2026 deadline to preserve potential claims; each press release notes counsel‑advertising disclaimers and offers consultations. The litigation’s outcomes, including any damages or remedies, will be determined through the courts and procedural stages such as class certification and possible lead plaintiff appointments.